Randomized Trial of Tenofovir Versus Lamivudine Plus Adefovir in Lamivudine Plus Adefovir Treated Lamivudine-resistant Chronic Hepatitis B Patients With Undetectable Hepatitis B Virus DNA.

Trial Profile

Randomized Trial of Tenofovir Versus Lamivudine Plus Adefovir in Lamivudine Plus Adefovir Treated Lamivudine-resistant Chronic Hepatitis B Patients With Undetectable Hepatitis B Virus DNA.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 May 2017

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Adefovir dipivoxil; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 15 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
    • 15 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top